razupenem

Small moleculeexperimental

Razupenem (PTZ-601) is a broad spectrum injectable antibiotic, from the carbapenem subgroup of beta-lactam antibiotics. It was developed as a replacement drug to combat bacteria that had acquired antibiotic resistance to commonly used antibiotics. Razupenem performed well against a variety of bacterial strains, but further development is in doubt due to a high rate of side effects in Phase II clinical trials. — Wikipedia

Clinical trial activity

1 trials · 1 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0

Earliest trial started May 1, 2008 (NCT00671580)

Timeline

2000s

  1. Jan 1, 2008

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

C[C@H]1C=C(c2csc(SC3=C(C(=O)O)N4C(=O)[C@H]([C@@H](C)O)[C@H]4[C@H]3C)n2)CN1
Mol. weight
407.52 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • pz-601
  • pz-601
  • razupenem
  • razupenem
  • razupenem
  • razupenem
  • sm-216601
  • sm-216601
  • smp-601
  • smp-601

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT00671580Phase 2May 1, 2008Protez Pharmaceuticals
Showing 1 of 1 trials
Page 1 / 1

Organizations

Research & Development (1)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Protez PharmaceuticalsFor profit1112008
1 organizations
Page 1 / 1